SCHEMBL1350402

SCHEMBL1350402

O=C(NC(c1ccccc1)C1(N2CCCC2)CCC1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTTP P55157 9/20 0.45
TSHR P16473 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2D6 P10635 1/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KLRK1 P26718 1/20 0.40
MICA Q29983 1/20 0.40
RAET1L Q5VY80 1/20 0.40
SLC6A9 P48067 2/20 0.40
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CACNA1A O00555 1/20 0.40
CACNA2D1 P54289 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348399 0.87 SLC6A9 (0.50) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1349648 0.85 SLC6A9 (0.44) KLRK1MICARAET1LSLC6A9
SCHEMBL1348590 0.85 SLC6A9 (0.49) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1350222 0.85 SLC6A9 (0.49) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1349999 0.84 SLC6A9 (0.50) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1350744 0.84 KLRK1 (0.50) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1349793 0.83 SLC6A9 (0.52) SLC6A9
SCHEMBL3241393 0.83 SLC6A9 (0.49) KLRK1MICARAET1LSLC6A9
SCHEMBL1349947 0.83 KLRK1 (0.41) MTTPKLRK1MICARAET1LSLC6A9
SCHEMBL1347772 0.82 SLC6A9 (0.53) MTTPCYP2C19CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063098-B2 GlyT1 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
US-8063098-B2 GlyT1 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
US-8063098-B2 GlyT1 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
US-20100048531-A1 GlyT1 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-02-25 US disclosed
US-20100048531-A1 GlyT1 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-02-25 US disclosed
US-20100048531-A1 GlyT1 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048531-A1 GlyT1 RECEPTOR ANTAGONISTS GLRA1, GLRA2, GRIA1 MTTP 1422/4885TSHR 821/4885CYP3A4 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.